Abeona Therapeutics Inc. (ABEO) News
Track canonical SquawkNews coverage tagged to ABEO, Abeona Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Weekly Recap: ZEVASKYN growth, expanded access and pipeline licensing
Abeona Therapeutics, Inc. (NASDAQ:ABEO) posted $11.4M ZEVASKYN revenue, up 31% QoQ, while expanding treatment reach—12 patients, seven centers covering ~40% of addressable patients and >95% payer coverage—and advanced it
NEWS | Sep 28, 2026, 11:03 AM UTC
M
Abeona eligible for milestones and royalties after FAYUVI approval
Abeona says Ultragenyx received FDA approval for FAYUVI (UX111), originally developed by Abeona as ABO-102, making Abeona eligible for commercial milestones and royalties under its 2022 out-licensing deal.
EQUITY | Sep 18, 2026, 11:32 AM UTC
M
ABEO rises after Roth Capital initiates Buy; Fayuvi FDA approval
ABEO closed up 4% Thursday and added 2% after-hours after Roth Capital initiated coverage at Buy with a $17 target; Ultragenyx’s Fayuvi gene therapy received late-session FDA approval.
EQUITY | Sep 17, 2026, 11:33 PM UTC
M
Abeona activates UF Health as 8th ZEVASKYN treatment center
Abeona Therapeutics activated University of Florida Health in Gainesville as the eighth Qualified Treatment Center for ZEVASKYN for RDEB patients.
EQUITY | Sep 16, 2026, 11:34 AM UTC
L
ABEO - Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
ABEO - Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
NEWS | Sep 16, 2026, 11:30 AM UTC
L
ABEO: ZEVASKYN's launch accelerates with expanding access, strong coverage, and promising patient outcomes
ZEVASKYN's U.S. launch is progressing with expanding treatment centers, robust reimbursement, and positive early patient outcomes. The addressable market exceeds $4 billion, with steady growth expected as more centers ga
EQUITY | Sep 09, 2026, 01:37 PM UTC
L
ABEO: Steady ZEVASKYN launch growth, expanding access, and strong pipeline signal major long-term potential
ZEVASKYN’s U.S. launch is progressing with expanding treatment center access, robust insurance coverage, and positive patient outcomes. Manufacturing capacity and foundational growth are scaling, with a $4B+ addressable
EQUITY | Sep 09, 2026, 01:01 PM UTC
L
Abeona Therapeutics management to participate in September investor conferences
Abeona Therapeutics said members of its management team will participate in upcoming investor conferences in September 2026, with live webcasts of fireside chats and the company presentation available via its Investors s
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
ABEO - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
ABEO - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
Abeona grants new-employee equity awards under Nasdaq Rule 5635(c)(4)
Abeona Therapeutics said it granted equity awards to new non-executive employees who joined the company, approved under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 11:37 AM UTC
L
Abeona Therapeutics announces new employee inducement grants
Abeona Therapeutics (ABEO) announced new employee inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 11:30 AM UTC
L
Abeona Therapeutics reports Q2 ZEVA Skin revenue of $11.4 million
Abeona Therapeutics said Q2 2026 ZEVA Skin revenue was $11.4 million, up 31% from Q1, after treating five patients in the quarter and expanding to seven activated QTCs.
EARNINGS | Aug 13, 2026, 03:07 PM UTC
M
Premarket selling hits CLBT, OTLK, STUB, ABEO, CBRS
CLBT, OTLK, STUB, ABEO and CBRS are indicated lower in premarket trading, with no catalyst or additional details supplied in the alert.
EQUITY | Aug 13, 2026, 11:55 AM UTC
L
Abeona Therapeutics (ABEO) reports Q2 2026 results; provides business update
Abeona Therapeutics reports second quarter 2026 results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
L
ABEO - Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ABEO - Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
EARNINGS | Aug 06, 2026, 11:30 AM UTC
H
Abeona Therapeutics Gains NTAP Status
Abeona's ZEVASKYN gets new tech payment status
EQUITY | Aug 04, 2026, 11:30 AM UTC
L
ABEO: Déclaration des actions et droits de vote au 30 juin 2026
ARTICLE 223-16 du règlement général de l'AMF Actions du capital
EQUITY | Jul 03, 2026, 04:04 PM UTC